Almirall mulls German exit after Sativex price drop
This article was originally published in Scrip
Executive Summary
Almirall may pull MS drug Sativex off the German market after tortuous price negotiations with the German Health Insurance Funds have resulted in the price being slashed by more than 60%. A senior Almirall manager said the new price "no longer covers the financing of the product". Leaving the product on the market at the lower price could have implications elsewhere through reference pricing.